Disclosures: Ahmed Elhariri: Nothing to Disclose, Manal Hassan: Nothing to Disclose, Mazen ELsheikh: Nothing to Disclose, Ahmed El sabagh: Nothing to Disclose, Mohamad Ali Ibrahim: Nothing to Disclose, Megha Bhongade: Nothing to Disclose, sali albarouki: Nothing to Disclose, Anish Nayak: Nothing to Disclose, Youseph Karouni: Nothing to Disclose, Prasun Jalal: Nothing to Disclose 1132 REAL-WORLD OUTCOMES OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) COMPENSATED CIRRHOSIS AT A LARGE ACADEMIC REFERRAL CENTER Shadera Slatter 1 Jordan Guillot 1 Christopher Williams 1 Alexandre Watanabe 2 Eirum Chaudhri 2 Xiao Zhang 2 Gail Fernandes 2 Jin Ge 3 Vivek Rudrapatna 1 , 1 Bakar Computational Health Sciences Institute, University of California, San Francisco, 2 Merck & Co., Inc., Rahway, NJ, USA, 3 University of California, San Francisco Background: Epidemiologic data on MASH compensated cirrhosis patients and their disease progression are limited

Botox May Work Less Effectively Facials done too early can weaken Botox effects
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
10.1016/j.micres.2022.127292 Microbiol
However, RCS analysis did not reveal a non-linear relationship
While interleukin-10 (IL-10) nanoparticles modulate local inflammation, their targeting efficacy requires optimization [62]